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KAJIAN IMUNOLOGI CALON VAKSIN DNA (pJWVacII) DAN VAKSIN 
‘SURFACE DISPLAY’ (r-STVacII) YANG MENGEKSPRESKAN GEN 
MULTIEPITOP SINTETIK MYCOBACTERUM TUBERCULOSIS DALAM 
STRATEGI ‘PRIME BOOST’ MENGGUNAKAN MODEL MENCIT. 
 
ABSTRAK 
 
 Tuberculosis (TB) pada manusia adalah disebabkan oleh patogen 
bakteria Mycobacterium tuberculosis dan merupakan salah satu penyakit utama 
di dunia. Satu-satunya vaksin TB yang terdapat pada masa ini ialah strain M. 
bovis yang telah dilemahkan iaitu, Bacille Calmette Guerin (BCG). 
Bagaimanapun, efikasi perlindungan BCG merangkumi julat 0 ke 80% di tempat 
kajian yang berlainan. Kesan perlindungan BCG adalah ketara pada kanak-
kanak tetapi tidak menunjukkan perlindungan terhadap TB paru-paru di 
kalangan orang dewasa yang menjadi masalah utama. Vaksin DNA merupakan 
salah satu cara baru untuk mengawal penyakit berjangkit dan boleh 
merangsang tindak balas kedua-dua sel humoral dan selular. Hasil kajian lepas, 
calon vaksin pJWVacII dan r-STVacII telah digunakan dalam kajian ini dengan 
menggunakan strategi ‘prime-boost’. Vaksin DNA, pJWVacII telah diberikan 
secara intraotot kepada mencit manakala vaksin ‘surface display' pula telah 
diberikan secara oral kepada mencit. Splenosit dari mencit yang diimunisasi 
telah diuji dengan pelbagai ujian keimunan. Keputusan menunjukkan bahawa 
splenosit dari mencit yang diimunisasi memberikan peningkatan gerak balas 
proliferasi apabila dirangsang dengan antigen (Inak-nVacII). Analisis sitokin 
intrasel ke atas splenosit juga menunjukkan kedua-dua CD4+ dan CD8+ sel T 
menghasilkan IL-2 dan IFN-γ berikutan rangsangan antigen. Dalam kaedah 
‘prime-boost’, kajian menunjukkan kaedah ‘prime’ dengan pJWVacII dan ‘boost’ 
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dengan r-STVacII adalah strategi terbaik untuk merangsang respon keimunan 
dalam mencit. Sebagai kesimpulan, data yang diperolehi dari kajian ini 
mencadangkan bahawa vaksin DNA digabungkan dengan vaksin ‘surface 
display’ menggunakan kaedah ‘prime-boost’ merupakan salah satu strategi 
baru untuk membangunkan calon vaksin terhadap TB. 
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IMMUNOLOGICAL STUDIES OF DNA (pJWVacII) AND SURFACE DISPLAY 
(r-STVacII) VACCINE CANDIDATES EXPRESSING A SYNTHETIC 
MULTIEPITOPE GENE OF MYCOBACTERIUM TUBERCULOSIS IN A PRIME 
BOOST STRATEGY USING A MOUSE MODEL 
 
ABSTRACT 
 
 Tuberculosis (TB) in humans is caused by the bacterial pathogen 
Mycobacterium tuberculosis and is still one of thea major health problems 
worldwide. The only TB vaccine currently available is an attenuated strain of M. 
bovis;, Bbacillei Calmette Guerin (BCG). BCG demonstrated variable protective 
efficacies ranging from 0 to 80% in different field trials. In addition, BCG 
prevents is effective at preventing childhood manifestation of TB but it does not 
prevent the most prevalent disease from which is pulmonary TB in adults. DNA 
vaccination is an new important new approach to the control of infectious 
agents and induces both humoral and cellular immune responses. Two 
pPreviously constructed vaccine candidates, pJWVacII and r-STVacII were 
used in this study applying employing a prime-boost strategy. The nNaked DNA 
vaccine, pJWVacII was given intramuscularly to mice whilst thee surface display 
vaccine, r-STVacII was given orally to mice. Splenocytes from the vaccinated 
mice were tested for various immunological tests. The results showed that 
splenocytes from immunized mice were found to proliferate more aggressively 
when stimulated with the antigen (Inak-nr-VacII). Flow cytometric intracellular 
cytokine analysis of splenocytes from vaccinated mice also showed that both 
CD4+ and CD8+ T cells produce IL-2 and IFN-γ following stimulation with the 
antigens. In the prime-boosting approach, the study was showed that mice 
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primed with the naked DNA vaccine, pJWVacII and boosted with the surface 
display vaccine, r-STVacII is the best strategy to stimulate immune response in 
mice. As a conclusion, the data obtained from this study suggest that DNA 
vaccination in combination with surface display vaccination using prime-boost 
approach provides a new strategy for developing a candidate vaccine against 
TB. 
 
ABSTRAK 
 
 Tuberculosis (TB) pada manusia adalah disebabkan oleh patogen bakteria 
Mycobacterium tuberculosis dan merupakan salah satu penyakit utama di dunia. Satu-
satunya vaksin TB yang terdapat pada masa ini ialah strain M. bovis yang telah 
dilemahkan iaitu, M. bovis Bbacille Calmette Guerin (BCG). Bagaimanapun, efikasi 
perlindungan BCG adalah berlainan darimerangkumi julat 0 ke 80% di tempat kajian 
yang berlainan. Tambahan pula, Kkesan perlindungan BCG adalah ketara pada kanak-
kanak tetapi tidak menunjukkan perlindungan terhadap TB paru-paru di kalangan orang 
dewasa yang menjadi masalah utama. Vaksin DNA merupakan salah satu cara baru 
untuk mengawal ejen infeksipenyakit berjangkit dan boleh merangsang tindak balas 
kedua-dua sel humoral dan selular. Hasil kajian lepas, calon vaksin pJWVacII dan r-
STVacII telah digunakan dalam kajian ini dengan menggunakan strategi ‘prime-boost’. 
Vaksin DNA, pJWVacII telah diberikan secara intraotot kepada mencit manakala 
vaksin ‘surface display' pula telah diberikan secara oral kepada mencit. Splenosit dari 
mencit yang diimunisasi telah diuji dengan pelbagai ujian keimunan. Keputusan 
menunjukkan bahawa splenosit dari mencit yang diimunisasi memberikan peningkatan 
gerak balas proliferasi apabila dirangsang dengan antigen (rVacII). Analisis sitokin 
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intrasel ke atas splenosit juga menunjukkan kedua-dua CD4+ dan CD8+ sel T 
menghasilkan IL-2 dan IFN-γ berikutan rangsangan antigen. Dalam kaedah ‘prime-
boost’, kajian menunjukkan kaedah ‘prime’ dengan pJWVacII dan ‘boost’ dengan r-
STVacII adalah strategi terbaik untuk merangsang respon keimunan dalam mencit. 
Sebagai kesimpulan, data yang diperolehi dari kajian ini mencadangkan bahawa vaksin 
DNA digabungkan dengan vaksin ‘surface display’ menggunakan kaedah ‘prime-boost’ 
merupakan salah satu strategi baru untuk membangunkan calon vaksin terhadap TB. 
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 1
CHAPTER 1 
INTRODUCTION 
 
 
1.1 Introduction to TB 
 Tuberculosis (TB) is a contagious and potentially fatal disease that can 
affect almost any part of the body but manifests mainly as an infection of the 
lungs. It is caused by a bacterial microorganism, the tubercle bacillus or 
Mycobacterium tuberculosis. TB infection can either be acute and short-lived or 
chronic and long-term. Approximately 1.7 billion people or one-third of the 
world’s population are infected with the predominant TB organism, M. 
tuberculosis. Currently, 10 to 15 million people in the United States have latent 
TB infection, and 10 percent of them will develop active disease at some point 
in their lives (Diana, 2000). 
 
Most people infected with M. tuberculosis never develop active TB. However, in 
people with weakened immune systems, especially those infected with the 
human immunodeficiency virus (HIV), TB organisms may overcome the body’s 
defenses, multiply, and cause active disease (Ellner, 1990). Each year, 8 million 
people worldwide develop active TB and 3 million die. TB is often one of the first 
secondary infections to be activated in HIV – positive individuals. Moreover, 
poverty, malnutrition and their contributing factors such as political 
disorganization and war also contribute to the increase rate of TB. Figure 1.1 
shows TB notification rate around the world. 
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 Figure 1.1: Tuberculosis notification rates, as of 22 March 2006 (Source: WHO Stop TB Department, 
website: www.who.int/tb) 
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1.2 History of TB 
 In the second half of the 17th century, when TB caused high levels of 
death rates in Europe, John Bunyan gave the title ‘captain of all these men of 
death’ for TB, which was also known as the white plaque. Pulmonary TB was 
known since the time of Hippocrates as phthisis, derived from the Greek for 
‘wasting away’. In 1680, the French, Franciscus Sylvius carried out anatomic-
pathologic studies in pulmonary nodules from TB patients, which he named as 
‘tubercula’ (small knots). These knots were believed to be only some type of 
tumor or abnormal gland. In 1722, a British doctor Benjamin Marten proposed 
that TB could be transmitted through the ‘breath’ of a sick person (reviewed by 
Rodrigo et al., 2006). 
 
In 1882, Robert Koch isolated and cultured M. tuberculosis from crushed 
tubercles and identified the bacterium as the TB etiological agent. In 1896, an 
American bacteriologist demonstrated that bovine TB was not caused by M. 
tuberculosis but by a closely related bacteriaby a closely related bacterium, M. 
bovis. Twelve years later, Albert Calmette and Camille Guerin isolated the 
bovine variant from its host and grew the bacilli in dispersed culture containing 
ox bile. After 13 years of experimentation, the variant was administered for the 
first time in humans orally, as an attempt to immunize a child whose mother 
died in childbirth as a victim of TB.  
 
However, WHO indicated that there have not been great effects on the global 
problem since the time of Koch (Bloom & Murray, 1992). Currently, TB causes 
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more human deaths than any other single infectious agent, standing for 26% of 
all preventable deaths and 7% of all deaths (reviewed by Rodrigo et al., 2006). 
 
1.3 Mycobacterium tuberculosis 
 The TB bacterium is a rod-shaped bacterium, non-motile, non-spore 
forming, 1-4 μm in length, and between 0.3-0.6 μm in diameter, making them 
smaller than most bacterial pathogens (Iseman, 2000 and Akemi et al., 2003). 
This bacterium belonging belongs to the family Mycobacteriaceae and the order 
Actinomycetales. M. tuberculosis, like other mycobacteria, has an unusual cell 
wall, a waxy coat comprised of fatty molecules whose structure and function are 
not well known. This cell wall appears to allow M. tuberculosis to survive in its 
preferred environment: inside immune cells called macrophages, which 
ordinarily degrade pathogens with enzymes. The coat of M. tuberculosis also 
renders it impermeableility to many common drugs. 
 
M. tuberculosis and other mycobacteria are also called as “acid fast” bacteria 
(AFB) which means that they retain certain dyes following an acid-alcohol 
decolorization step and this characteristic is related to the complex cell wall 
structure that contains derivatives of mycolic acid (Floyd et al., 1992). In tThe 
most common staining technique, Ziehl-Neelsen stain, AFB isare stained a 
bright red  which stands out clearly against a blue background. It is also can 
also be visualized by fluorescent microscopy and by auramine-rhodamine stain 
(Batzing, 2002).  
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There are several factors that contribute to the difficulty of in the study of M. 
tuberculosis in the laboratory. First, the bacteria multiply very slowly, only once 
every 24 hours and take a month to form a colony. Two media are often used to 
grow M. tuberculosis;, Middlebrook’s medium which is an agar based medium 
and Lowenstein-Jensen medium which is an egg based medium (American 
Thoracic Society, 2000).  
 
In comparison, other organism such as E. coli form colonies within eight hours. 
Moreover, TB bacilli tend to form clumps which are difficult to work with or to 
count themthe cells. Most daunting, M. tuberculosis is a dangerous, airborne 
organism that can be studied only in laboratories that have specialized safety 
equipment. 
 
Several species of mycobacteria with similar growth characteristics and 
biochemical reactions are classified together into as the M. tuberculosis 
complex (Cole, 2002). This complex includes M. bovis, M. africanum and M. 
microti which can also causes TB in mammals. The first two are very rare 
causes of disease and the last one do not cause human disease (Brosch et al., 
2000). 
 
1.3.1 The cell wall of M. tuberculosis 
 Mycobacteria produce an extremely uncommon cell wall structure. It is 
composed of a multilayered cell envelope which basically consista multilayered 
cell envelope which basically consists of ( from inside the cells to the outer 
surface) : a plasma membrane and three covalently associated macromolecules 
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such as peptidoglycan, arabinogalactan and mycolic acid or glycolipids (Figure 
1.2). The plasma membrane is composed of a thicker outer leaflet and a thinner 
inner leaflet. The pPlasma membrane was observed is thought to be to be a 
smooth, asymmetrical stained structure closely associated with the 
peptidoglycan layer, with a narrow constant space between them (Akemi et al., 
2003). 
 
 
Figure 1.2: Schematic representation of the mycobacterial cell wall (Adapted 
from Rodrigo et al., 2006) 
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a thicker outer leaflet and a thinner inner leaflet. The plasma membrane is 
thought to be a smooth, asymmetrical stained structure closely associated with 
the peptidoglycan layer, with a narrow constant space between them (Akemi et 
al., 2003). 
 
 
 
 
 
The pPeptidoglycan layer tangentially intrudesd into the cytoplasma and formed 
a septal wall together with the plasma membrane. The width of the 
peptidoglycan layer of M. tuberculosis was measured found to be approximately 
10-15 nm (Akemi et al., 2003) and contains N-glycolylmuramic acid instead of 
the usual N-acetylmuramic acid, which is found amongst most other bacteria. 
TFrom the he mycobacterial cell envelope study carried out by Rastogi (1991) 
show the, there is a presence of an arabinogalactan layer on the peptidoglycan 
which is attached by a phosphodiester links. This compound is supposed 
thought to be richly found in the cell wall of M. tuberculosis and to be 
responsible for the thickening of the cell wall (Akemi et al., 2003). Approximately 
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10% of the arabinose residues in the arabinogalactan are substituted by mycolic 
acids (Mc Neil & Brennan, 1991). 
 
Mycolic acids are branched fatty acids that have a short and a long branch with 
22 to 24 and 40 to 64 carbons respectively (Jarlier & Nikaido, 1994). The cell 
wall also contains several other free lipid species, which are not covalently 
attached to this basal skeleton (the mycolylarabinogalactan-peptidoglycan 
complex). These lipids can act as antigens in the host (Brennan & Nikaido, 
1995). In the arabinogalactan polysaccharide, both galactan main chain and 
arabinan side branches are designed structured in such a manner that would 
ensures maximum mobility between sugar residues. The mycolic acid residues 
are esterified to approximately two-thirds of the non-reducing termini of this 
highly branched polysaccharide (Mc Neil & Brennan, 1991). 
 
Furthermore, the mycobacterial cell wall fluidity gradient appears to have an 
opposite orientation compared to all Gram-negative bacteria as the more 
external regions are more fluid than the internal ones. Amongst mycobacterial 
species, M. tuberculosis is one of the most permeable to hydrophilic 
antimycobacterial agents and thereby, less resistant to such drugs (for instance, 
etham-butol) (Brennan & Nikaido, 1995).  
 
Since mycobacteria are relatively resistantce to drying, alkali and many other 
chemical disinfectants, it is thus very difficult to prevent M. tuberculosis 
transmission in urban institution environments. This resistance to therapeutic 
such external agents is basically conferred by the extremely uncommon 
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mycobacterial cell wall structure (Brennan & Nikaido, 1995). The unusual cell 
wall also permits the microorganism to survive inside the macrophages which 
that would usually destroy phagocytosed pathogens (NSB Editorial Comment, 
2000). 
 
1.3.2 Genome of M. tuberculosis 
 M. tuberculosis has a circular chromosome with of 4,411,529 base pairs 
with a 65.6% G+C content. Although the M. tuberculosis genome is smaller than 
that of E. coli, it is very versatile, coding for most of the typical bacterial anabolic 
and catabolic pathways and amino acid synthesis/degradation (Cole et al., 
1998). The feature that differentiates M. tuberculosis from any other bacteria is 
the presence of a genome with approximately 4000 genes, mostly coding for 
enzymes involved in lipogenesis lipolysis (for bacterial survival insides its host) 
and lipolysis lipogenesis (for cellular envelope synthesis and turnover).  There 
have been atAt least 2 prophages have been detected in its genome.,  
 
Analyses of the genome suggest that this pathogen may be able to alter protein 
expression patterns thus presenting to its host’s immune system as a moving 
target and therefore interfering in protective immunological responses, which 
can be involved with the fact that M. tuberculosis has a low lysis level in culture. 
Through protein expression pattern alteration, these pathogens can be 
presented to their host’s immune system as a moving target, interfering in the 
immunological response by antigen processing inhibition. Thereby, ensuring a 
greater survival probability to the bacteria (Cole et al., 1998). 
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1.4 Transmission of TB 
 TB is primarily an airborne disease. The disease is not likely to be 
transmitted through personal items belonging to those with TB, such as 
clothing, bedding or other items they have touched. TB is spread from person to 
person in droplets nuclei expelled from the lungs when a TB sufferer coughs, 
sneezes, sings or laughs. Adequate ventilation is the most important measure 
to prevent the transmission of TB. This is because most infected people expel 
relatively few bacilli and, transmission of TB usually occurs only after prolonged 
exposure to someone with active TB.  
 
Most people are likely to be contagious when their sputum contains bacilli. This 
happens when they cough frequently and when the extent of their lung disease 
as revealed by a chest x-ray, is great. Only people with active disease are 
contagious. Droplet nuclei are tiny and remain in the air for prolonged periods, 
ready to be inhaled. They are small enough to bypass the natural defenses of 
upper respiratory passages such as hairs in the nose or the hair like cilia in the 
bronchial tubes. Infection begins when the bacilli reaches the tiny air sacs of the 
lungs known as alveoli, where they multiply within macrophages (Schluger & 
Rom, 1998 and, Frieden et al., 2003). People who have been treated with 
appropriate drugs for at least two weeks usually will not become infectious. 
 
There are three factors that influence transmission of M. tuberculosis. First is 
the number of viable bacilli in patient’s sputum and their concentration in the air. 
Secondly, the length of time an exposed person breathes the contaminated air 
and thirdly, the immune status of the exposed individuals (Horsburgh, 1996). 
 11
 
1.5 Pulmonary and extrapulmonary TB 
1.5.1 Pulmonary TB 
Pulmonary TB is TB that affects the lungs, and represents about 85% of 
newly diagnosed cases diagnosed. It usually presents with a cough, which may 
or may not produce sputum. In time, more sputum is produced that is streaked 
with blood. The cough may be present for weeks or months and may be 
accompanied by chest pain and shortness of breath. Persons with pulmonary 
TB often run a low-grade fever and suffer from night-sweats. The patient often 
loses interest in food and may lose weight. If the infection allows air to escape 
from the lungs into the chest cavity (pneumothorax) or if fluid collects in the 
pleural space (pleural effusion), the patient may have difficulty breathing. The 
TB bacilli may travel from the lungs to lymph nodes in the sides and back of the 
neck. Infection in these areas can break through the skin and discharge pus. 
 
 
 
1.5.2. Extrapulmonary TB 
Although the lungs are the major sites of damage caused by TB, many 
other organs and tissues in the body may be affected. About 15% of newly 
diagnosed cases of TB are extrapulmonary, with a higher proportion of these 
being HIV-infected persons. The usual progression of the disease is to begin in 
the lungs (Figure 1.3) and spread to locations outside the lungs. In some cases, 
however, the first sign of disease appears outside the lungs.  
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Tissues or organs that may be affected by TB include bones, kidneys, female 
reproductive organs, abdominal cavity, joints and meninges. All parts of the 
body such as skin, intestines, adrenal glands and blood vessels can be also 
infected by M. tuberculosis (Bloom and Murray, 1992).  
 
Miliary TB is a life-threatening condition that occurs when large numbers of 
tubercle bacilli spread throughout the body. Huge numbers of tiny tubercular 
lesions develop that cause marked weakness and weight loss, severe anemia 
and gradual wasting of the body. 
 
1.6 Symptoms of TB 
 TB bacteria become active if the immune system cannot stop them from 
growing. The active bacteria begin to multiply in the body and cause active TB 
disease. The bacteria attack the body and destroy tissues. If this occurs in the 
lungs, the bacteria can actually create a hole in the lung. Some people develop 
active TB disease soon after becoming infected, before their immune system 
can fight the TB bacteria. Other people may get sick later, when their immune 
system becomes weak. 
 
In most people who breathe in an environment with containing the TB bacteria 
and become infected, the body is able to fight the bacteria to stop them from 
growing. The bacteria become inactive, but they remain alive in the body and 
can become active later. This is called latent TB infection. Many people who 
have latent TB infection never develop active TB disease. In these people, the 
TB bacteria  
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Figure 1.3: Progression of TB in the lung. Granulomas from Mycobacterium 
tuberculosis will spread to locations outside the lungs or called as 
extrapulmonary TB (Adapted from ADAM Health Illustrated Encyclopedia, 
2006). 
 
 
 
 
 
 
 
 
 
 
Granulomas from 
M. tuberculosis 
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can fight the TB bacteria. Other people may get sick later, when their immune 
system becomes weak. 
 
In most people who breathe in an environment containing the TB bacteria and 
become infected, the body is able to fight the bacteria to stop them from 
growing. The bacteria become inactive, but they remain alive in the body and 
can become active later. This is called latent TB infection. Many people who 
have latent TB infection never develop active TB disease. 
 
 
 
 
 
In these people, the TB bacteria remain inactive for a lifetime without causing 
disease. However, in other people, especially people who have weak immune 
systems, the bacteria become active and cause TB disease. Table 1.1 shows 
the differences between latent TB infection and active TB disease. 
 
1.7 Immune response to TB 
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 M. tuberculosis is a very successful pathogen that can survive and 
persist in the human host in the face of a robust immune response. Although 
the organism can multiply within the macrophage, it can still be inhibited and  
killed when the macrophage is activated. There are two antimycobacterial 
mechanisms of in macrophages that can result in destruction of mycobacteria. 
First, macrophages can produce nitric oxide and related reactive nitrogen 
intermediates (RNIs) via the action of the form of nitric oxide synthase (NOS2). 
Following RNI and NOS2 production, IFN-γ and TNF-α were induced as an 
antimycobacterial activity (Flynn, 2004). 
 
Another antimycobacterial mechanism of macrophage is phagolysome fusion in 
which which containsphagosomes containing ingested bacteria fuses with 
lysosomes containing degradative enzymes and other antibacterial substances. 
and This is a primary mechanism by which macrophages control infection. This 
Ffusion will increase when the macrophage is activated by IFN-γ or other 
cytokines. Unfortunately, M. tuberculosis that is initially within a phagosome, 
then can also inhibit phagolysome fusion and acidification in “non-activated” 
macrophages. Therefore, the mycobacteria can avoid being killed by the 
macrophages. 
 
 
 
Table 1.1: The differences between latent TB infection and active TB disease 
(National Adapted from Centers for HIV/AIDS, Viral Hepatitis, STD and TB 
PreventionDisease Control & Prevention, 20076) 
 
A Person with Latent TB Infection A Person with Active TB Disease 
• Has no symptoms  • Has symptoms that may 
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• Does not feel sick  
• Cannot spread TB to others  
• Usually has a positive skin test 
or QuantiFERON-TB® Gold test 
• Has a normal chest x-ray and 
sputum test  
include:  
• a bad cough that lasts 3 
weeks or longer  
• pain in the chest  
• coughing up blood or 
sputum  
• weakness or fatigue  
• weight loss  
• no appetite  
• chills  
• fever  
• sweating at night  
• May spread TB to others  
• Usually has a positive skin test 
or QuantiFERON®-TB Gold test 
• May have an abnormal chest x-
ray, or positive sputum smear 
or culture  
 
 
 
 
 
 
 
 
 
 
 
 
Another antibacterial mechanism of macrophage is phagolysome fusion in 
which phagosomes containing ingested bacteria fuses with lysosomes 
containing degradative enzymes and other antibacterial substances. This is a 
primary mechanism by which macrophages control infection. Fusion will 
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increase when the macrophage is activated by IFN-γ or other cytokines. 
Unfortunately, M. tuberculosis that is initially within a phagosome, can also 
inhibit phagolysome fusion and acidification in “non-activated” macrophages. 
Therefore, the mycobacteria can avoid being killed by the macrophages. 
 
 
 
 
 
 
 
 
 
 
 
1.7.1 Early host response 
 The site of initial infection is usually the alveoli, the balloon-like sacs at 
the end of the small air passages in the lungs known as bronchioles. In the 
alveoli, white blood cells called macrophages ingest the inhaled M. tuberculosis 
bacilli (reviewed by van Crevel et al., 2002). Some of the bacilli may be killed 
immediately and others may multiply within the macrophages. Infrequently, but 
especially in HIV-infected people and in children, the bacilli spread to other sites 
in the body (reviewed by van Crevel et al., 2002). This dissemination sometimes 
results in life-threatening meningitis and other problems. 
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During the two to eight weeks after initial infection in people with intact immune 
systems, macrophages present pieces of the bacilli, displayed on their cell 
surfaces to another type of white blood cell, the T cell. Upon stimulation, T cells 
release an elaborate array of chemical signals. Once cell-mediated 
hypersensitivity is established, a person’s T cells usually will respond to the 
tuberculin skin test (PPD test) and produce a characteristic red welt (NIAID, 
1997). Some of the T cell signals produce inflammatory reactions, other signals 
recruit and activate specialized cells to kill bacilli and wall-off the infected 
macrophages in tiny, hard grayish capsules known as tubercles. 
 
From then on the body’s immune system maintains a standoff with the infection, 
sometimes for years. TB bacilli may persist within macrophages but further 
multiplication and spreading of M. tuberculosis are confinedrestricted. Most 
people undergo complete healing of their initial infection and the tubercles 
calcify and lose their viability. A positive TB skin test and in some cases a chest 
x-ray may provide the only evidence of the infection. If, however, the body’s 
resistance is low because of aging, infections such as HIV, malnutrition or other 
factors, the bacilli may break out of the tubercles in the alveoli and lead to active 
disease (Kaufmann & Ulrichs, 2003). 
 
The phagocytosis and the subsequent secretion of IL-12 are processes initiated 
in the absence of prior exposure to an antigen and hence form a component of 
innate immunity. The components of innate immunity are natural resistance 
associated macrophage protein (Nramp 1), neutrophils, natural killer cells (NK) 
and Toll-like receptors (TLR). Plasma lysozyme and other enzymes also may 
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play an important role in the first line defence of innate immunity to M. 
tuberculosis (Selvaraj et al., 2001). 
 
Nramp 1 is crucial in transporting nitrite from intracellular compartments such as 
the cytosol to more acidic environments like phagolyisosome, where it can be 
converted to nitric oxide (NO). Defects in Nramp 1 production increase 
susceptibility to mycobacteria. However, Nramp 1 gene might not be associated 
with the susceptibility to pulmonary and spinal TB in the Indian population 
(Selvaraj et al., 2002). Increased accumulation of neutrophil in the granuloma 
and increased chemotaxis has suggested a role for neutrophils (Edwards et al., 
1986). Majeed et al. (1998) have shown that neutrophils can bring about killing 
of M. tuberculosis in the presence of calcium under in vivo conditions. 
 
Natural killer (NK) cells are also the effector cells of innate immunity. These 
cells may directly lyse the pathogens or can lyse infected monocytes. NK 
culture with live M. tuberculosis brought about the expansion of NK cells 
implicating that they may be an important responders to M. tuberculosis 
infection in vivo (Esin et al., 1996). During early infection, NK cells are capable 
of activating phagocytic cells at the site of infection. IL-2 activated NK cells can 
bring about mycobacterial activity in macrophages infected with M. avium 
complex (MAC) as a non- specific response (Bermudez & Young, 1991). NK 
cells can also produce IFN-γ and can lyse mycobacterium- pulsed target cells 
(Molloy et al., 1993). Furthermore, augmentation of NK activity with cytokines 
implicates them as a potential adjunct to TB chemotherapy (Nirmala et al., 
2001). 
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TLR is another component that plays an important role in immunity against TB. 
The interactions between M. tuberculosis and TLRs are complex and it appears 
that distinct mycobacterial components may interact with different members of 
the TLR family. M. tuberculosis can immunologically activate cells via either 
TLR2 or TLR4 in a CD14-independent, ligand-specific manner (Means et al., 
1999). 
 
1.7.2 Host specific immune mechanisms in TB 
 M. tuberculosis is equipped with numerous immune evasion strategies, 
including modulation of antigen presentation to avoid elimination by T cells. M. 
tuberculosis-infected macrophages appear to be diminished in their ability to 
present antigens to CD4+ T cells, which leads to persistent infection (Hmama et 
al., 1998). Another mechanism by which antigen presenting cells (APCs) 
contribute to defective T cell proliferation and function is by the production of 
cytokines, including TGF-β, IL-10 (Rojas et al., 1999) or IL-68 (van Heyningen 
et al., 1997). In addition, it has also been reported that virulent mycobacteria 
were able to escape from fused phagosomes and multiply (Moreira et al., 1997). 
 
1.7.2(a) Humoral immune response 
 Since M. tuberculosis is an intracellular pathogen, the serum 
components may not get access to it and may not play any important protective 
role. However, aAlthough many researchers have dismissed a role for B cells or 
antibody in protection against TB (Johnson et al., 1997), recent studies suggest 
that these immune components may contribute to the response to TB (Bosio et 
 21
al., 2000). Several protein antigens of M. tuberculosis have been identified 
using murine monoclonal antibodies (Lingers et al., 1986). The 
immunodominant antigens for mice include 71, 65, 38, 23, 19, 1.4 and 12 kDa 
proteins.  
 
A number of M. tuberculosis antigens have been purified for diagnostic used 
(Lima Devi et al., 2001, Demkow et al., 2002, Raja et al., 2002 and Ramalingam 
et al., 2002). Combinations of antigens waswere also found to be useful in the 
diagnosis of TB (Ramalingam et al., 2003). Detection of circulating immune 
complex- bound antibody was found to be more sensitive as compared to 
serum antibodies. The purified antigens were evaluated for their utility in 
diagnosing infection (Senthil Kumar et al., 2000). 
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1.7.2(b) Cellular immune response 
 M. tuberculosis is a pathogen for which the protective response relies on 
cell mediated immunity (CMI). In the mouse model, within one week of infection 
with virulent M. tuberculosis, the number of activated CD4+ and CD8+ T cells in 
the lung draining lymph nodes increases (Feng et al., 1999). In principle, three 
processes that contributescontribute to the cellular immune response are; 
antigen presentation, co-stimulation and cytokine production (van Crevel et al., 
2002). 
 
Mycobacterial antigens presentation by macrophages and dendritic cells trigger 
T-cells response in the context of major histocompatibility complex (MHC). MHC 
molecules include class I and class II are involved in for the presentation of 
mycobacterial antigens (Flynn, 2004). Antigen presentation involves CD4+ T-
cells, CD8+ T-cells and unconventional T-cells including CD1 restricted T cells 
(van Crevel et al., 2002).  
 
After processing mycobacterial antigens in the phagolysosomal compartments 
of professional antigen-presenting cells (APCs), MHC class II molecules 
present these mycobacterial proteins to antigen specific CD4+ T cells. The 
effector functions of CD4+ T cells are sufficient to activate macrophages. 
Basically, the effector function of CD4+ T cells can be further divided into two, 
which are Th1 and Th2 type.  
 
Th1 secretes cytokines such as IL-2, IFN-γ, TNF-α and IL-12 resulting in 
macrophage activation and induction of CMI. Most data obtained from animal 
 23
models suggest that Th1 cells and IFN-γ are the major effectors that lead to 
macrophage activation (Kaufmann & Anderson, 1998). In contrast, Th2 secretes 
IL-4, IL-5, IL-6 and IL-10 resulting in the induction of humoral immunity by 
antibody production. The HIV epidemic has demonstrated that the loss of CD4+ 
T cells greatly increases susceptibility of the host to both acute and reactivation 
TB (reviewed by Flynn, 2004). 
 
 
Meanwhile, MHC class I molecules present mycobacterial proteins to antigen-
specific CD8+ T-cells, which will lead to the killing of infected cells from following 
peptide-MHC recognition. This cytolytic functions of cytotoxic T lymphocytes 
(CTL) releases a cytolytic molecule, perforin which will induce apoptosis in 
infected cells (Esser et al., 2003). It was suggested that CTL killing of the 
bacteria depends on their ability to deliver potent bactericidal proteins such as 
granulysin from their granules (Silva et al., 2001). Lysise of target cells by CD8+ 
T cells can occur via perforin and granzymes or the Fas/FasL (CD95L) pathway 
resulting in apoptotic cell death or release of bacteria from an infected cell into 
the granuloma (Canaday et al., 2001). 
 
As mentioned earlier, unconventional T cells such as CD1 and γδ T cells also 
appear to play a have roles in host defense against mycobacterial infection. 
Both cells produce type  1 cyokines, most importantly IFN-γ which activates 
anti- mycobacterial activities in macrophage (Raupach & Kaufmann, 2001). 
CD1 restricted αβ T-lymphocytes are thought to be activated by mycobacterial 
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lipids whereas γδ T-lymphocytes are activated by small phosphorylated 
metabolites (Agger & Anderson, 2002). 
 
Both CD4+ and CD8+ T lymphocytes as well as unconventional T cells such as 
γδ T-cells and double-negative αβ T-cells subsets are involved in immunity to 
TB (Andersen, 2001). The pulmonary immune response in resistant mice was 
characterized by an early influx of both CD4+ and CD8+ lymphocytes that 
produced IFN-γ (Alissa et al., 2001). These results suggest an important role for 
the early appearance of IFN-γ producing lymphocytes in the lung in resistance 
to M. tuberculosis infection with M. tuberculosis.  
 
A study on animal models of TB have suggested that both CD4+ and CD8+ T-
cells have a protective roles in M. tuberculosis infection (Cooper and Flynn, 
1995). Within one week of infection with virulent M. tuberculosis, the number of 
activated CD4+ and CD8+ T-cells in the lung during lymph nodes increases 
(Serbina et al., 2000). Meanwhile, between 2 to 4 weeks post-infection, both 
CD4+ and CD8+ T-cells migrate to the lungs and demonstrate an effector 
phenotype (Feng et al., 1999 and Serbina et al., 2000). Both CD4+ and CD8+ T-
cells are also found in the granuloma to prevent spreading or reactivation (Flynn 
et al., 1992). 
 
Co-stimulation is the second process that leads to the initiation of cellular 
immunity. Antigen presentation only leads to T cell stimulation in the presence 
of several co-stimulatory signals. B-7.1 (CD80) and B-7.2 (CD86) are the most 
well known co-stimulatory signals for T cell stimulation. These co-stimulatory 
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